“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in AUD
Last close As at 28/03/2023
AUD0.07
— 0.00 (0.00%)
Market capitalisation
AUD31m
Australian-based Chimeric Therapeutics recently went public on the ASX. CLTX CAR T is in Phase I for the treatment of GBM. The technology may have applicability for other tumours such as melanoma. Chimeric recently in-licensed a CDH17 CAR T for use in solid tumours and the CORE-NK platform, which may have broad applicability in cancer.
Managing Director - Head of Content, Healthcare
Jennifer Chow
CEO
Paul Hopper
Executive Chairman
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (8.9) | (11.1) | (65.3) |
| Relative | (13.9) | (17.9) | (66.4) |
| 52 week high/low | A$0.2/A$0.1 |
Chimeric has announced that it has entered into an exclusive option agreement to license the clinically validated, off the shelf, robust, enhanced natural killer (CORE-NK) cell platform from Case Western Reserve University for the treatment of cancer. The CORE-NK platform was designed to overcome the hurdles associated with NK cell development and enables the production of large numbers of highly active universal donor NK cells that are active in the body. The company expects to rapidly move to complete full licensing of the platform.
| Y/E Jun | Revenue (A$m) | EBITDA (A$m) | PBT (A$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.0 | (0.1) | (0.1) | (6200.80) | N/A | N/A |
| 2021A | 0.0 | (14.8) | (14.9) | (8.16) | N/A | N/A |
| 2022E | 0.0 | (14.0) | (14.0) | (4.19) | N/A | N/A |
| 2023E | 0.0 | (14.5) | (14.5) | (4.32) | N/A | N/A |
